NeuClone to Initiate P-I Clinical Study of Stelara (ustekinumab- biosimilar) in Australia
Shots:
- Neuclone plans for the onset of P-I clinical study for NeuLara- a Stelara's biosimilar evaluating NeuLara vs the US & EU score of Stelara in healthy candidates in Australia under CTN scheme of TGA in H2'19
- NeuLara is developed utilizing NeuMAX technology & Right from the Start development approach- analytically tested with X-ray crystallography for the confirmation of the identical structure b/w NeuLara and Stelara
- J&J's Stelara (ustekinumab) is a mAb targeting IL-12 and IL-23- approved for moderate to severe plaque psoriasis in adults and children aged ≥12yrs and has generated $5.2B revenue in 2018. NeuLara X-ray Crystallography is technique allowing 3-D imagining of complex molecules
Click here to read full press release/ article | Ref: PRNewsWire | Image: NeuClone
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com